The U.S. Food and Drug Administration granted accelerated approval on Thursday to Bristol Myers Squibb’s Zenbexus, known generically as iberdomide, for the treatment of adult patients with multiple myeloma. The approval covers use of the drug in combination with daratumumab, hyaluronidase-fihj, and dexaméthasone—a regimen designated as ZDd—for patients who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent.
Clinical Trial Results and Regulatory Milestones
According to data from the phase 3 EXCALIBER-RRMM trial, the accelerated approval rests on a median follow-up of 16 months comparing the ZDd combination against a control arm of daratumumab, bortézomib, and dexaméthasone, referred to as DVd. Results showed that 41 % of patients receiving the ZDd regimen achieved a complete response with negative minimal residual disease, compared to 21 % of patients treated in the DVd arm. Minimal residual disease negativity is an indicator of response depth and a predictor of improved progression-free survival. This decision marks the first regulatory approval in relapsed or refractory multiple myeloma based on a complete response with minimal residual disease negativity, according to the sources. Zenbexus received breakthrough therapy designation and underwent review through the FDA’s Project Orbis initiative, which facilitates concurrent evaluations across multiple international health authorities.
Safety Profile and Adverse Reactions
According to ch.zonebourse.com, the ZDd combination carries significant safety warnings, including risks of severe, life-threatening, or fatal infections and severe neutropenia. According to trial safety data reported by ch.zonebourse.com, neutropenia and infections occurred in significant portions of patients receiving ZDd. The most frequent adverse reactions included upper respiratory tract infections, fatigue, musculoskeletal pain, pneumonia, diarrhea, motor disorders, rashes, sleep disorders, hypogammaglobulinemia, COVID-19, and constipation. Serious adverse reactions comprised pneumonia, upper respiratory tract infections, second primary cancers, neutropenia, febrile neutropenia, COVID-19, and sepsis. Fatal adverse reactions occurred in 10 patients, with sepsis identified as the only fatal drug reaction affecting more than one patient.
Market Projections and Financial Analyst Outlooks
Financial analysts have adjusted market models following the regulatory decision. According to a research note from William Blair, the list price for Zenbexus is approximately 29 500 dollars per 28-day cycle, exceeding prior pricing assumptions. Analyst Matt Phipps updated financial projections to estimate that U.S. sales for Zenbexus will surpass a billion dollars per year by early 2031. Full regulatory approval for the indication remains contingent upon verification and description of clinical benefit in confirmatory trials. Meanwhile, Bristol Myers Squibb maintains an active new drug application for another investigational cereblon E3 ligase modulator, mezigdomide, in combination with carfilzomib and dexamethasone, with a Prescription Drug User Fee Act target action date set for May 2027.